GlassScriptPhysician profile
Chetan Khamare
NPI 1871783217
$11,631.76
in general payments reported to CMS, 2019-2025
42 companies · $2,645 in 2025
The $2,645 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $758 · 2021: $522 · 2022: $1,916 · 2023: $2,113 · 2024: $2,354 · 2025: $2,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,999 · Education: $94.99 · Travel and Lodging: $17.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,999.25 |
| Education | $94.99 |
| Travel and Lodging | $17.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,354.54 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $1,339.78 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $1,216.90 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $980.43 | 2019-2025 | Jardiance |
| Medtronic, INC. | $929.07 | 2021-2025 | Onyx Frontier, Linq II, Micra |
| Janssen Pharmaceuticals, INC | $732.99 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $669.17 | 2021-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $615.18 | 2019-2025 | Diamondback Peripheral, Assurity, Xience Skypoint |
| Novartis Pharmaceuticals Corporation | $525.63 | 2019-2025 | |
| Boston Scientific Corporation | $518.79 | 2019-2025 | Sq-Rx Pulse Generator, General - Crm_crm, Lux-Dx Insertable Cardiac Monitor |
| Medtronic Vascular, INC. | $262.24 | 2019-2020 | |
| Pfizer INC. | $258.45 | 2019-2025 | |
| Recor Medical INC | $249.94 | 2024 | Paradise Renal Denervation System |
| Actelion Pharmaceuticals US, INC. | $216.02 | 2019-2025 | Opsumit, Uptravi |
| Cvrx, INC. | $205.29 | 2022-2023 | Barostim Neo System |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $159.09 | 2019-2025 | Repatha, Repatha |
| Penumbra, INC. | $153.29 | 2019-2023 | Indigo System |
| Scpharmaceuticals INC. | $134.65 | 2023-2025 | |
| Biom'Up Sa | $111.02 | 2019 | |
| Abiomed | $109.69 | 2024-2025 | Impella |
| Sanofi-Aventis U.S. LLC | $103.16 | 2019-2023 | |
| Novo Nordisk INC | $91.76 | 2021-2025 | Wegovy, Ozempic |
| Infobionic, INC | $90.99 | 2024 | Mome Device |
| Biom'Up France Sas | $72.72 | 2020 | |
| Inari Medical, INC. | $61.69 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Esperion Therapeutics, INC. | $61.66 | 2021-2023 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $53.54 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.55 | 2025 | |
| Kestra Medical Technology Services, INC. | $45.12 | 2022-2023 | Assure Wcd |
| Terumo Medical Corporation | $38.24 | 2024 | Glidesheath Slender |
| Cashflow Solutions, LLC | $33.18 | 2024-2025 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
| Kiniksa Pharmaceuticals International, Plc | $22.28 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $20.44 | 2019 | |
| Angiodynamics, INC. | $19.57 | 2025 | Alphavac |
| Astellas Pharma US INC | $17.46 | 2019 | |
| Heartflow, INC. | $17.10 | 2022 | |
| Biotronik INC. | $16.41 | 2019 | |
| Organogenesis INC. | $16.35 | 2021 | |
| Shockwave Medical, INC | $15.73 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.60 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $14.51 | 2023 | Arcalyst |
| Smith+Nephew, INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chetan Khamare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.